Open data
|
Deployed on AWS
The Molecular Profiling to Predict Response to Treatment (MP2PRT) program is part of the NCI's Cancer Moonshot Initiative. The aim of this program is the retrospective characterization and analysis of biospecimens collected from completed NCI-sponsored trials of the National Clinical Trials Network and the NCI Community Oncology Research Program. This study, titled "Identification of Genetic Changes Associated with Relapse and/or Adaptive Resistance in Patients Registered as Favorable Histology Wilms Tumor on AREN03B2", performs genomic characterization (WGS 30X, Total RNAseq, miRNAseq) on a discovery set of 70 trio cases (normal tissue, tumor tissue at time of diagnosis, tumor tissue at time of relapse) from patients who relapsed with Favorable Histology Wilms Tumor. Prioritized findings from the discovery set will be validated using Targeted Sequencing in an independent validation set of 47 relapse samples. The MP2PRT study is made available on AWS via the NIH STRIDES Initiative[...]
Overview
The Molecular Profiling to Predict Response to Treatment (MP2PRT) program is part of the NCI's Cancer Moonshot Initiative. The aim of this program is the retrospective characterization and analysis of biospecimens collected from completed NCI-sponsored trials of the National Clinical Trials Network and the NCI Community Oncology Research Program. This study, titled "Identification of Genetic Changes Associated with Relapse and/or Adaptive Resistance in Patients Registered as Favorable Histology Wilms Tumor on AREN03B2", performs genomic characterization (WGS 30X, Total RNAseq, miRNAseq) on a discovery set of 70 trio cases (normal tissue, tumor tissue at time of diagnosis, tumor tissue at time of relapse) from patients who relapsed with Favorable Histology Wilms Tumor. Prioritized findings from the discovery set will be validated using Targeted Sequencing in an independent validation set of 47 relapse samples. The MP2PRT study is made available on AWS via the NIH STRIDES Initiative (https://aws.amazon.com/blogs/publicsector/aws-and-national-institutes-of-health-collaborate-to-accelerate-discoveries-with-strides-initiative/ ).
Features and programs
Open Data Sponsorship Program
This dataset is part of the Open Data Sponsorship Program, an AWS program that covers the cost of storage for publicly available high-value cloud-optimized datasets.
Pricing
This is a publicly available data set. No subscription is required.
Legal
Content disclaimer
Vendors are responsible for their product descriptions and other product content. AWS does not warrant that vendors' product descriptions or other product content are accurate, complete, reliable, current, or error-free.
Delivery details
AWS Data Exchange (ADX)
AWS Data Exchange is a service that helps AWS easily share and manage data entitlements from other organizations at scale.
Open data resources
Available with or without an AWS account.
- How to use
- To access these resources, reference the Amazon Resource Name (ARN) using the AWS Command Line Interface (CLI). Learn more
- Description
- miRNA Sequencing, Total RNA Sequencing, Whole Genome Sequencing, Targeted Sequencing
- Resource type
- S3 bucket
- Amazon Resource Name (ARN)
- arn:aws:s3:::gdc-mp2prt-wt-phs001965-2-open
- AWS region
- us-east-1
- AWS CLI access (No AWS account required)
- aws s3 ls --no-sign-request s3://gdc-mp2prt-wt-phs001965-2-open/
Resources
Vendor resources
Support
How to cite
Molecular Profiling to Predict Response to Treatment (phs001965) was accessed on DATE from https://registry.opendata.aws/mp2prt .
Similar products
GROMACS is an open-source molecular dynamics engine, offered here with additional charges for configuration, automation, and technical support. This AMI delivers a fully optimized HPC environment with GPU acceleration, MPI support, scientific libraries, VMD visualization, BioBB workflow automation modules, and Amazon DCV remote access ideal for high-performance molecular simulation and analysis.
SG4D100M is a state-of-the-art molecular foundation model that revolutionizes drug discovery and chemical development. Built on advanced transformer architecture with SE(3) invariance, it enables accurate molecular property prediction and structural analysis across pharmaceutical, specialty chemical, and agricultural applications.
This AMI allows users to run a proprietary Freecurve Labs MD package to predict various properties of different molecular ensembles: proteins, RNAs, DNAs, ligands, etc.
Nach01 is a language foundation model designed for AI-driven drug discovery, enabling fine-tuning and efficient molecular property prediction to accelerate your DMTA cycle.
Get to the winning molecule faster! Discover drugs, chemicals, catalysts, and materials faster and at lower cost. This modern ab initio SaaS platform allows high accuracy molecular simulations at unprecedented speeds. Unrivaled performance, accuracy, and capabilities make this platform an indispensable part of the discovery process.